Skip to main content
OSR Holdings, Inc. logo

OSR Holdings, Inc. — Investor Relations & Filings

Ticker · OSRH ISIN · US68840D1028 US Professional, scientific and technical activities
Open in API
Filings indexed 204 across all filing types
Latest filing 2024-11-14 Major Shareholding Noti…
Country US United States of America
Listing US OSRH

About OSR Holdings, Inc.

https://osr-holdings.com/

OSR Holdings, Inc. is a healthcare holding company that operates using a hub-and-spoke model to manage a diverse portfolio of subsidiary companies. The company's vision is to accelerate healthcare innovation to improve health and wellness outcomes. It actively evaluates and pursues merger and acquisition opportunities that advance innovative healthcare, either by addressing unmet patient needs or by lowering patient costs and burden. The firm's development activities are focused on a portfolio of therapies and healthcare solutions, including oral immunotherapies for cancer treatment, design-augmented biologics, therapeutic antibodies, and engineered proteins.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-14 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2024, reporting on the results of an annual meeting of stockholders. It details the approval of proposals to amend the company's charter, including extending the deadline for a business combination and removing a net tangible asset requirement. It also includes voting results for these proposals and the election of directors. The document is focused on the submission of matters to a vote of security holders and the outcomes of those votes. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not an annual report, earnings release, or management report, but specifically reports voting results from the annual meeting. The length and content confirm it is not merely an announcement of a report but a substantive filing of voting results.
2024-11-12 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from K&L Gates LLP to the U.S. Securities and Exchange Commission regarding comments on an Amendment No. 1 to a Registration Statement on Form S-4 filed by Bellevue Life Sciences Acquisition Corp. The content includes responses to SEC staff comments on the Form S-4, which is a registration statement used in business combinations, mergers, or acquisitions involving securities. The document discusses pro forma financial information, ownership structure, accounting treatments, and disclosures related to a business combination transaction. It is not the registration statement itself but a letter addressing SEC comments and revisions to the Form S-4. This type of document is a regulatory correspondence related to a merger/acquisition filing but is not the merger filing itself. Given the nature of the document as a response letter to SEC comments on a Form S-4 registration statement, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and compliance documents that do not fit other specific categories. The document is not a full report, financial statement, or presentation, nor is it an announcement or proxy material. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2024-11-08 English
S-4/A
Merger & Acquisition Classification · 95% confidence The document is a Form S-4 Registration Statement filed with the SEC, which is used for registering securities in connection with business combinations such as mergers or acquisitions. The text references a Business Combination Agreement, share exchanges, lock-up agreements, and ownership percentages post-combination. It also includes a preliminary proxy statement/prospectus related to a special meeting for stockholder approval of the business combination. These characteristics align with filings related to merger and acquisition activities. The document is not a full annual or quarterly report, nor is it an earnings release or proxy solicitation alone. It is a regulatory filing specifically for a merger transaction. Therefore, the most appropriate classification is Merger & Acquisition (MA).
2024-11-08 English
ARS
Annual Report
2024-10-28 English
DEF 14A
Proxy Solicitation & Information Statement
2024-10-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.